Implant Sciences [IMSC] has introduced a bench-top explosives and narcotics trace detector, the Quantum Sniffer QS-B220, it plans to offer for checkpoint screening applications worldwide. The B220 doubles Implant’s product portfolio to two devices. The company has sold about 1,400 of its QS-H150 handheld explosives trace detectors, tallying over $30 million in sales. The B220 features no radioactive materials, which means no licensing costs, annual testing and end-of-life disposal issues. The device also has a built-in automatic calibration system and doesn’t require disposables related to calibration. The company also said the B220 has a rapid clear down. The narcotics trace detection capabilities also offer potential new markets for the company at border crossings and prisons, Implant says. “We anticipate that the QS-B220 will help drive increasing revenues through our expanding sales channels,” says Glenn Bolduc, Implant’s CEO.